109 related articles for article (PubMed ID: 8146723)
1. [Pulmonary functions in patients with progressive systemic sclerosis].
Takaya M; Ichikawa Y; Shimizu H; Moriuchi J; Uchiyama M; Arimori S
Ryumachi; 1994 Feb; 34(1):2-9. PubMed ID: 8146723
[TBL] [Abstract][Full Text] [Related]
2. [Pulmonary manifestation of progressive systemic scleroderma: prognostic value of centromere antibodies and antibodies to Scl-70 nucleoprotein].
Behr J; König G; Meurer M; Krieg T
Pneumologie; 1990 Jun; 44(6):822-5. PubMed ID: 2381889
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody.
Steen VD; Lucas M; Fertig N; Medsger TA
J Rheumatol; 2007 Nov; 34(11):2230-5. PubMed ID: 17937469
[TBL] [Abstract][Full Text] [Related]
4. Static lung mechanics in patients of progressive systemic sclerosis without obvious pulmonary involvement.
Gupta D; Aggarwal AN; Sud A; Jindal SK
Indian J Chest Dis Allied Sci; 2001; 43(2):97-101. PubMed ID: 11529415
[TBL] [Abstract][Full Text] [Related]
5. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement.
Steen V; Medsger TA
Arthritis Rheum; 2003 Feb; 48(2):516-22. PubMed ID: 12571862
[TBL] [Abstract][Full Text] [Related]
6. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
Khanna D; Clements PJ; Furst DE; Chon Y; Elashoff R; Roth MD; Sterz MG; Chung J; FitzGerald JD; Seibold JR; Varga J; Theodore A; Wigley FM; Silver RM; Steen VD; Mayes MD; Connolly MK; Fessler BJ; Rothfield NF; Mubarak K; Molitor J; Tashkin DP;
Arthritis Rheum; 2005 Feb; 52(2):592-600. PubMed ID: 15692967
[TBL] [Abstract][Full Text] [Related]
7. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline.
Plastiras SC; Karadimitrakis SP; Ziakas PD; Vlachoyiannopoulos PG; Moutsopoulos HM; Tzelepis GE
Arthritis Rheum; 2006 Aug; 55(4):598-602. PubMed ID: 16874782
[TBL] [Abstract][Full Text] [Related]
8. [Change of pulmonary diffusing capacity, membrane diffusing capacity and pulmonary capillary blood volume in patients with COPD and connective tissue disease at rest and post-exercise].
Chi L; Liu Y; Piao Z
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jun; 21(6):344-7. PubMed ID: 11326890
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up study of pulmonary findings in patients with primary Sjögren's syndrome.
Pertovaara M; Korpela M; Saarelainen S; Laitinen J; Järvenpää R; Laippala P; Lahdensuo A
Scand J Rheumatol; 2004; 33(5):343-8. PubMed ID: 15513685
[TBL] [Abstract][Full Text] [Related]
10. [Changes in pulmonary function in SARS patients during the three-year convalescent period].
Liu YX; Ye YP; Zhang P; Chen J; Ye H; He YH; Li N
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2007 Sep; 19(9):536-8. PubMed ID: 17767822
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies in systemic sclerosis.
Steen VD
Semin Arthritis Rheum; 2005 Aug; 35(1):35-42. PubMed ID: 16084222
[TBL] [Abstract][Full Text] [Related]
12. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis.
Jacobsen S; Ullman S; Shen GQ; Wiik A; Halberg P
J Rheumatol; 2001 Nov; 28(11):2454-9. PubMed ID: 11708418
[TBL] [Abstract][Full Text] [Related]
13. [Effect of pneumothorax on membrane diffusing capacity and pulmonary capillary blood volume].
Zeng M; Xie C; Li Z
Zhonghua Jie He He Hu Xi Za Zhi; 1999 Apr; 22(4):242-4. PubMed ID: 11775924
[TBL] [Abstract][Full Text] [Related]
14. [An autopsied case of progressive systemic sclerosis with anti Wa antibody who showed a rapid progression].
Abe T; Yachi A; Ishii Y; Takeshima Y; Yonezawa K; Ishibashi F; Tosaka M; Tanifuji J; Yoshida Y; Takano S
Ryumachi; 1992 Oct; 32(5):488-94. PubMed ID: 1440086
[TBL] [Abstract][Full Text] [Related]
15. Association of esophageal dysfunction and pulmonary function impairment in systemic sclerosis.
Lock G; Pfeifer M; Straub RH; Zeuner M; Lang B; Schölmerich J; Holstege A
Am J Gastroenterol; 1998 Mar; 93(3):341-5. PubMed ID: 9517636
[TBL] [Abstract][Full Text] [Related]
16. Anti-DNA topoisomerase II alpha autoantibodies in Japanese patients with systemic sclerosis.
Hayakawa I; Hasegawa M; Takehara K; Sato S
Arch Dermatol Res; 2005 Oct; 297(4):180-3. PubMed ID: 16180014
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
[TBL] [Abstract][Full Text] [Related]
18. Non-invasive diagnostic and functional evaluation of cardiac and pulmonary involvement in systemic sclerosis.
Sergiacomi G; De Nardo D; Capria A; Manenti G; Fabiano S; Borzi M; De Sanctis G; Konda D; Sperandio M; Schillaci O; Masala S; Simonetti G; Fontana L
In Vivo; 2004; 18(2):229-35. PubMed ID: 15113051
[TBL] [Abstract][Full Text] [Related]
19. [The correlations of respiratory function tests, chest roentgenographic manifestations and respiratory symptoms in the patients with systemic sclerosis, using a scoring-method for symptoms].
Kikuchi K; Igarashi A; Ishibashi Y; Inokuma S; Takehara K
Nihon Hifuka Gakkai Zasshi; 1990 May; 100(6):695-700. PubMed ID: 2214236
[TBL] [Abstract][Full Text] [Related]
20. [Longitudinal study of parameters of respiratory function tests and blood gas analysis in patients with progressive systemic scleroderma].
Georgiev O; Shoshkov P; Rashkov R
Vutr Boles; 2001; 33(2-3):37-40. PubMed ID: 12001574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
